These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28784002)

  • 21. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C; García A; Blasco AJ; Lázaro P
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficiency of biologic agents in the treatment of moderate to severe psoriasis].
    Blasco AJ; Lázaro P; Ferrándiz C; García-Díez A; Liso J
    Actas Dermosifiliogr; 2009 Nov; 100(9):792-803. PubMed ID: 19889301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
    Martin S; Feldman SR; Augustin M; Szapary P; Schenkel B
    J Dermatolog Treat; 2011 Jun; 22(3):138-43. PubMed ID: 21254886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
    Alfageme Roldán F; Bermejo Hernando A; Calvo González JL; Marqués Sánchez P
    Rev Esp Salud Publica; 2016 Apr; 90():E15. PubMed ID: 27073006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
    Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
    Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
    Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
    J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle.
    Chi CC; Wang SH
    Biomed Res Int; 2014; 2014():862851. PubMed ID: 24605338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
    D'Souza LS; Payette MJ
    J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
    Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
    J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.
    Igarashi A; Igarashi A; Graham CN; Gilloteau I; Tani Y
    J Med Econ; 2018 Oct; ():1-9. PubMed ID: 30289010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.
    Avgerinou G; Bassukas I; Chaidemenos G; Katsampas A; Kosmadaki M; Kousoulakou H; Petridis A; Schenkel B; Sotiriadis D; Spiliopoulos T; Stavropoulos P; Toumpi E; Xaplanteris L
    BMC Dermatol; 2012 Jul; 12():10. PubMed ID: 22831458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
    Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D
    BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.